FDA accepts Lundbeck's submission of the New Drug Application for clobazam
The NDA submission is based on a clinical development program that evaluated the safety and efficacy of OnfiTM as add-on therapy in patients with LGS. Positive results from the largest clinical phase III trial ever conducted in patients with LGS were presented at the December 2010 annual meeting of the American Epilepsy Society (AES).
LGS is a rare and severe form of epilepsy that is typically diagnosed in childhood and often persists into adulthood. Most patients with LGS experience multiple types of seizures with periods of frequent seizures, and daily seizures are common. Some of these seizures may cause falls, or "drop seizures," which may result in injury.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.